Gefitinib

Gefitinib (Iressa®) is an orally administered tyrosine kinase inhibitor (TKI) of the epidermal growth factor receptor (EGFR). It is FDA-approved for the first-line treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 19 deletions or exon 21 (L858R) substitution mutations, as detected by an FDA-approved test.